findmyKOL
Clinical trialNCT05973084RecruitingObservational

COVID-19 Transmission and Morbidity in Malawi

SponsorBoston UniversityEnrollment1,500SARS CoV 2 InfectionSARS CoV 2 Vaccination
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the Americas. To identify what is different requires a better understanding of the underlying immunological substrate of the population, and how these factors affect susceptibility to infection, progression of symptoms, transmission, and responses to SARS-CoV-2 vaccination. Study objectives 1. Determine the risk and predictors of infection and disease among contacts of SARS-CoV-2 infection subjects in Malawi 2. Determine whether innate immune responses lower the risk of SARS-CoV-2 infection and disease, and acquisition and duration of vaccine responses. 3. Assess whether alterations in innate immune responses relevant to SARS-CoV-2 are associated with malaria or intestinal parasite infections. 4. Assess the acquisition and longevity of antibodies (Ab) and cellular adaptive responses elicited by SARS-CoV-2 infection and vaccination. 5. Assess whether malaria and intestinal parasite infections, chronic/mild undernutrition, and anemia mediate alterations in Ab and other adaptive cellular responses to SARS-CoV-2 through innate immune responses or a different unknown mechanism.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Clarissa Valim, MD ScD

    BU School of Public Health, Department of Global Health

    Principal Investigator
  • Don Mathanga, MBBS PhD

    Kamuzu University of Health Sciences, Malaria Alert Center, Malawi

    Principal Investigator
  • James Beeson, MBBS PhD

    Burnet Institute, Australia

    Principal Investigator
  • Patricia Hibberd, MD PhD

    BU School of Public Health, Department of Global Health

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Malawi
  • Health Center

    Blantyre, Malawi

    Don Mathanga, MBBS PhD
    Recruiting
United States
  • Bu School of Public Health, Global Health Department

    Boston, Massachusetts, United States

    Active, not recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Jan 2023
Primary completion
31 Mar 2028
Completion
31 Mar 2028
Last update posted
28 May 2026
Registered enrollment
1,500
Registry id
NCT05973084

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.